Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease

In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase 2 trial of haploidentical bone marrow transplant in sickle cell disease.

Featured Articles

Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies
Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated Thrombotic Thrombocytopenic Purpura
An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Om avsnittet

Fler avsnitt

Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

Dose Makes the Cure: Venetoclax in Ph- ALL

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow

Predictive Markers of Glofitamab Resistance in R/R B-NHL

Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

FLT3-ITD microclones in AML and Results from the RESET-PV trial